SRPX2 and pachyonychia congenita: In this study, we observed that high basal SRPX2 level and upward change of serum SRPX2 level were reflective of unfavorable prognosis among PC patients who received chemotherapies (Figures 1, 2 and Table 1), which implied that SRPX2 might be indicative of chemotherapeutic efficacy of PC patients.